ARK 每周股评 – 11/6/2021

我们每周都会与投资者分享我们策略中一周内一天内升值或下跌超过15%的股票的周评。我们希望您觉得这篇评论有用。

We share weekly commentaries with investors on stocks in our strategies that have appreciated or dropped more than 15% in a day during the course of the week. We hope you find this commentary useful.

Nextdoor Holdings (KIND)
+17%Shares of Nextdoor Holdings (KIND) traded up almost 17% on Monday after completing the merger with its SPAC. Nextdoor provides a hyperlocal social networking platform that connects users and businesses within their neighborhoods.

注: 在完成与SPAC的合并后,Nextdoor Holdings (KIND)的股价周一上涨近17%。Nextdoor提供了一个超本地化的社交网络平台,将用户和他们社区内的企业联系起来。
Invitae (NVTA)
-22%Invitae (NVTA), a leading provider and manager of clinical genetic data, closed down nearly 22% on Tuesday following its third-quarter earnings call. Despite growing revenue 66% year-over-year, Invitae missed revenue expectations and lowered its annual revenue guidance. We believe investors also were disappointed by a decrease in gross margin, which the company noted was due to a quarterly product mix that heavily emphasized lower-margin reproductive testing. While we sympathize with investor frustration, we commend Invitae’s decision to release a 14-metric dashboard each quarter that should help analysts better understand Invitae’s increasingly complex business. We continue to believe Invitae’s broad testing menu, powerful digital capabilities, and technology stack make the company a leader in genetic information management. Finally, we estimate that Invitae’s oncology products and completion of new production facilities should increase operating leverage and gross margin in 2022.

注: 领先的临床基因数据供应商和管理者Invitae (NVTA)在其第三季度财报电话会议后,周二收盘下跌近22%。尽管收入同比增长66%,但Invitae没有达到收入预期,并降低了其年度收入指导。我们认为投资者也对毛利率的下降感到失望,该公司指出这是由于季度产品组合严重强调了利润率较低的生殖测试。虽然我们同情投资者的挫折感,但我们赞扬Invitae决定每季度发布一个14个指标的仪表板,这应该有助于分析师更好地了解Invitae日益复杂的业务。我们仍然相信,Invitae广泛的测试菜单、强大的数字能力和技术堆栈使该公司成为基因信息管理的领导者。最后,我们估计Invitae的肿瘤学产品和新的生产设施的完成应该在2022年提高经营杠杆和毛利率。
Roblox (RBLX)
+42%Shares of Roblox (RBLX) traded up 42% on Tuesday after reporting strong third quarter earnings, with revenue up 102% year-over-year (YoY) and average daily active users up 31% YoY to 47.3 million. We maintain high conviction in Roblox’s ability to attract developers and end users. Despite post-pandemic reopening dynamics, we believe user-oriented gaming platforms will continue to benefit from sticky users. Roblox is an online entertainment platform that allows users to engage with a variety of virtual worlds and games that independent developers create and offer through the platform itself.

注: Roblox(RBLX)的股票在周二上涨了42%,此前该公司公布了强劲的第三季度收益,收入同比增长102%,日均活跃用户同比增长31%至4730万。我们对Roblox吸引开发者和终端用户的能力保持高度的信心。尽管大流行后的重新开放动态,我们相信面向用户的游戏平台将继续从粘性用户中受益。Roblox是一个在线娱乐平台,允许用户参与各种虚拟世界和游戏,这些虚拟世界和游戏是由独立开发者创造并通过平台本身提供。
The Trade Desk (TTD)
+29%Shares of The Trade Desk (TTD) traded up 29% on Tuesday after reporting strong third quarter earnings. The Trade Desk reported growth outpacing programmatic advertising growth during its third quarter, with total revenue up 39% year-over-year (YoY). With the continued expansion of its Unified ID 2.0 ecosystem, we believe The Trade Desk has a leading edge in attracting agencies and publishers looking to diversify away from Apple’s IDFA changes and third-party cookies. The Trade Desk is an ad-tech company that facilitates audience targeting across different media formats.

注: The Trade Desk (TTD)的股价周二上涨了29%,此前该公司公布了强劲的第三季度收益。The Trade Desk在第三季度的增长超过了程序化广告的增长,总收入同比增长39%。随着其Unified ID 2.0生态系统的持续扩张,我们相信The Trade Desk在吸引那些希望从苹果IDFA变化和第三方cookie中多样化的代理机构和出版商方面具有领先优势。The Trade Desk是一家广告技术公司,促进了不同媒体格式的受众定位。
Recursion (RXRX)
-18%Recursion (RXRX), a clinical-stage, AI-enabled drug discovery company, traded down nearly 18% on Wednesday after issuing its quarterly press release. Given the company’s early stage, we believe investors may have sold in anticipation of increased investment spending by Recursion ahead of several programs that will enter the clinic in 2022. We believe Recursion’s approach to small molecule drug discovery is unique and becoming increasingly validated as its programs enter clinical studies.

注: Recursion(RXRX)是一家处于临床阶段的人工智能药物发现公司,周三在发布其季度新闻稿后,交易量下降了近18%。鉴于该公司处于早期阶段,我们认为投资者可能是在预期Recursion将在2022年进入临床的几个项目之前增加投资支出而卖出。我们相信Recursion的小分子药物发现方法是独特的,并且随着其项目进入临床研究而日益得到验证。
Toast (TOST)
-18%Shares of Toast (TOST) traded down 18% on Wednesday after posting third-quarter results that missed analysts’ bottom-line estimates. Toast beat top-line revenue estimates and grew its total payment volume by 123% year-over-year. Toast offers innovative point-of-sale software and payments to restaurants in the US.

注: Toast (TOST)周三股价下跌18%,此前该公司公布的第三季度业绩未达到分析师的底线预期。Toast公司的收入超出预期,其总支付量同比增长了123%。Toast向美国的餐馆提供创新的销售点软件和支付。
Opendoor (OPEN)
+15%Shares of Opendoor (OPEN) traded up 15% on Thursday after the company reported third-quarter earnings that, in contrast to those from Zillow (Z), benefited from solid iBuying execution, appearing to validate the business model. Opendoor is an iBuying real estate platform that takes the friction out of the home-buying and selling process.

注: Opendoor(OPEN)周四股价上涨15%,此前该公司公布的第三季度收益与Zillow(Z)相反,受益于坚实的iBuying执行,似乎验证了其商业模式。Opendoor是一个iBuying房地产平台,消除了购房和销售过程中的摩擦。
Compugen (CGEN)
-18%On Thursday, Compugen (CGEN), an Israeli pharmaceutical company focused primarily on innovative treatments for a range of cancer indications, traded up 14% on news that Bristol Myers Squibb expanded their collaboration and invested an additional $20M in Compugen’s stock. At the Society for Immunotherapy of Cancer (SITC), Compugen also presented data on its monotherapy (COM902), an antibody targeting a protein called TIGIT, that showed anti-tumor activity in 9 of 18 patients (50%) but no better response than “stable disease”. Compugen also presented data from its Phase 1 dose escalation study from a triple therapy containing Opdivo®, BMS-986207, and “COM701”, an inhibitor of PVRIG (poliovirus receptor related immunoglobulin). Trial participants tolerated this triple therapy well but showed limited to no response. Expecting complete or partial responses from this data release, many investors sold CGEN, pushing the stock down approximately 18% today.

注: 周四,以色列制药公司Compugen(CGEN),主要专注于一系列癌症适应症的创新治疗,因有消息称百时美施贵宝扩大了他们的合作,并向Compugen的股票追加了2000万美元的投资,交易量上升了14%。在癌症免疫治疗协会(SITC)上,Compugen公司还展示了其单药治疗(COM902)的数据,这是一种针对一种名为TIGIT的蛋白质的抗体,在18名患者中的9名(50%)显示出抗肿瘤活性,但没有比 “稳定疾病 “更好的反应。Compugen公司还公布了包含Opdivo®、BMS-986207和PVRIG(脊髓灰质炎病毒受体相关免疫球蛋白)抑制剂 “COM701 “的三联疗法的一期剂量升级研究数据。试验参与者对这种三联疗法的耐受性良好,但显示出有限的甚至没有反应。由于期望从这个数据发布中得到完全或部分反应,许多投资者卖出了CGEN,使该股今天下跌了约18%。
Farfetch (FTCH)
+17%Shares of Farfetch (FTCH) traded up 17% today after the company confirmed it is in discussions with luxury conglomerate Richemont to potentially expand their Luxury New Retail partnership. Potential directions include Farfetch powering the ecommerce backend of Richemont’s brands and YOOX NET-A-PORTER, and the participation of Richemont’s brands in Farfetch’s marketplace. We believe Richemont’s openness to collaborate further is a testament to Farfetch’s technological edge in e-concession and logistics optimization. Farfetch provides an online luxury shopping platform, and we believe it is a leader in digitizing the luxury experience around the world.

注: Farfetch(FTCH)的股价今天上涨了17%,此前该公司证实它正在与奢侈品集团历峰集团讨论可能扩大他们的奢侈品新零售合作。潜在的方向包括Farfetch为历峰集团旗下品牌和YOOX NET-A-PORTER的电商后台提供支持,以及历峰集团旗下品牌参与Farfetch的市场。我们相信历峰集团对进一步合作的开放态度,证明了Farfetch在电子特许经营和物流优化方面的技术优势。Farfetch提供了一个在线奢侈品购物平台,我们相信它是全球奢侈品体验数字化的领导者。
Vuzix (VUZI)
+15%Shares of Vuzix (VUZI) traded up 15% today in response to continued bullish sentiment from investors. Vuzix reported third quarter earnings on Monday and, although it missed Wall Street expectations for revenue, management reiterated confidence in an acceleration in sequential revenue growth for the fourth quarter. Vuzix offers AR display and computing glasses for consumer and enterprise markets globally.

注: Vuzix(VUZI)的股票今天上涨了15%,以回应投资者持续的看涨情绪。Vuzix周一公布了第三季度财报,尽管它的收入没有达到华尔街的预期,但管理层重申了对第四季度收入连续加速增长的信心。Vuzix为全球消费者和企业市场提供AR显示和计算眼镜。

主题测试文章,只做测试使用。发布者:star,转转请注明出处:http://wallstreetgm.com/ark-%e6%af%8f%e5%91%a8%e8%82%a1%e8%af%84-11-6-2021-2/

发表评论

您的电子邮箱地址不会被公开。 必填项已用*标注